IMMIX BIOPHARMA, INC. Accumulated Other Comprehensive Income
IMMIX BIOPHARMA, INC. (IMMX) had Accumulated Other Comprehensive Income of $118.72 thousand as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-07
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $118.72K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $105.64K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $60.16K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $62.46K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | $118.72K 10-Q · filed 2026-08-07 |
| 2026-03-31 | $105.64K 10-Q · filed 2026-05-07 |
| 2025-12-31 | $60.16K 10-Q · filed 2026-08-07 |
| 2025-09-30 | $62.46K 10-Q · filed 2025-11-07 |
| 2025-06-30 | $65.03K 10-Q · filed 2025-08-08 |
| 2025-03-31 | $15.46K 10-Q · filed 2025-05-08 |
| 2024-12-31 | -$1.06K 10-K/A · filed 2026-03-27 |
| 2024-09-30 | $192.05K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $116.97K 10-Q · filed 2024-08-12 |
| 2024-03-31 | $89.61K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $134.67K 10-K · filed 2025-03-25 |
| 2023-09-30 | $46.73K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $80.88K 10-Q · filed 2023-08-11 |
| 2023-03-31 | $82.55K 10-Q · filed 2023-05-12 |
| 2022-12-31 | $87.02K 10-K · filed 2024-03-29 |
| 2022-09-30 | $62.05K 10-Q · filed 2022-11-09 |
| 2022-06-30 | $102.44K 10-Q · filed 2022-08-12 |
| 2022-03-31 | $141.00K 10-Q · filed 2022-05-13 |
| 2021-12-31 | $125.41K 10-K · filed 2023-03-27 |
| 2020-12-31 | $131.86K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |